As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
8 Analysts have issued a Medicenna Therapeutics Corp forecast:
8 Analysts have issued a Medicenna Therapeutics Corp forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -16 -16 |
19%
19%
|
|
| EBIT (Operating Income) EBIT | -16 -16 |
20%
20%
|
|
| Net Profit | -9.32 -9.32 |
50%
50%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
| Head office | Canada |
| CEO | Fahar Merchant |
| Employees | 16 |
| Founded | 2015 |
| Website | www.medicenna.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


